Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments

被引：6
|
作者：
Roeb, Elke [1 ,2 ]
Geier, Andreas [3 ]
机构：
[1] Justus Liebig Univ, Dept Gastroenterol, Giessen, Germany
[2] Univ Hosp Giessen, Giessen, Germany
[3] Univ Hosp Wurzburg, Div Hepatol, Wurzburg, Germany
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2019年 / 57卷 / 04期
关键词：
non alcoholic fatty liver disease; steato hepatitis; liver fibrosis; FATTY LIVER-DISEASE; FIBROSIS; ELASTOGRAPHY; BIOPSY; NAFLD; METAANALYSIS; DIAGNOSIS; RISK;
D O I：
10.1055/a-0784-8877
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of increasing type 2 diabetes and obesity. This article reviews the scientific findings of epidemiology, diagnostic, and therapeutic management of NAFLD. Lifestyle modifications (low-caloric Mediterranean diet and exercise training) to reduce weight are a major factor in the treatment of NAFLD. Pharmacological therapies may be useful in patients with NASH and fibrosis as well as nonresponders to lifestyle modifications. Currently, however, no pharmacological substances are approved for the indication NASH.
引用
收藏
页码：508 / 517
页数：10
相关论文
共 50 条
  • [41] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [42] The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis
    Ralf Weiskirchen
    Frank Tacke
    Current Hepatology Reports, 2018, 17 (4) : 324 - 335
  • [43] Dietary treatment of nonalcoholic steatohepatitis
    Perito, Emily R.
    Rodriguez, Luis A.
    Lustig, Robert H.
    CURRENT OPINION IN GASTROENTEROLOGY, 2013, 29 (02) : 170 - 176
  • [44] Perspectives on Treatment for Nonalcoholic Steatohepatitis
    Lassailly, Guillaume
    Caiazzo, Robert
    Pattou, Francois
    Mathurin, Philippe
    GASTROENTEROLOGY, 2016, 150 (08) : 1835 - 1848
  • [45] Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
    Lefere, Sander
    Devisscher, Lindsey
    Tacke, Frank
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 89 - 92
  • [46] Current medical treatment for NAFLD/NASH
    Masrour, Oumnia
    Bardou-Jacquet, Edouard
    NUTRITION CLINIQUE ET METABOLISME, 2023, 37 (02): : 72 - 76
  • [47] Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
    Savari, Feryal
    Mard, Seyed Ali
    HELIYON, 2024, 10 (07)
  • [48] Ultrasound imaging in nonalcoholic liver disease: current applications and future developments
    Yang, Kuen Cheh
    Liao, Yin-Yin
    Tsui, Po-Hsiang
    Yeh, Chih-Kuang
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2019, 9 (04) : 546 - 551
  • [49] Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Ahn, Sang Bong
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S150 - S156
  • [50] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
12345